Driehaus Capital Management LLC Has $52.40 Million Position in TransMedics Group, Inc. $TMDX

Key Points

• Driehaus Capital Management LLC increased its stake in TransMedics Group, owning 778,754 shares valued at approximately $52.4 million, representing a 2.4% increase.
• A number of analysts have upgraded their ratings for TransMedics Group, with Oppenheimer raising the price target from $130 to $150 and maintaining an "outperform" rating.
• TransMedics Group reported a 37.7% increase in quarterly revenue year-over-year, achieving $157.37 million, significantly surpassing the consensus estimate of $146.64 million.

Driehaus Capital Management LLC grew its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 778,754 shares of the company's stock after buying an additional 17,913 shares during the quarter. Driehaus Capital Management LLC owned 2.30% of TransMedics Group worth $52,395,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMDX. NBC Securities Inc. bought a new stake in shares of TransMedics Group during the 1st quarter valued at approximately $25,000. Smartleaf Asset Management LLC grew its holdings in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares during the last quarter. Hager Investment Management Services LLC grew its holdings in shares of TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the last quarter. CWM LLC grew its holdings in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after purchasing an additional 155 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of TransMedics Group by 55.6% during the 1st quarter. AlphaQuest LLC now owns 1,288 shares of the company's stock valued at $87,000 after purchasing an additional 460 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Down 1.5%

Shares of NASDAQ:TMDX traded down $1.76 during trading on Monday, reaching $114.96. The stock had a trading volume of 665,581 shares, compared to its average volume of 942,848. The firm's fifty day moving average is $119.99 and its 200 day moving average is $103.59. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $172.78. The stock has a market cap of $3.92 billion, a price-to-earnings ratio of 59.57 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same period in the prior year, the firm posted $0.35 EPS. The company's quarterly revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TMDX shares. Wall Street Zen lowered shares of TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Oppenheimer boosted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $123.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.